Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Laboratories, |
RCV006448589 | SCV007321935 | benign | not specified | 2025-09-26 | criteria provided, single submitter | clinical testing | BA1, BS2, BP4, BP7 |
| Breakthrough Genomics, |
RCV004714111 | SCV005279666 | benign | not provided | criteria provided, single submitter | not provided | ||
| Labcorp Genetics |
RCV000872444 | SCV001014256 | benign | Mucopolysaccharidosis, MPS-II | 2026-02-02 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002318886 | SCV000851973 | benign | Inborn genetic diseases | 2017-07-09 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Natera, |
RCV000872444 | SCV001462903 | benign | Mucopolysaccharidosis, MPS-II | 2020-09-16 | no assertion criteria provided | clinical testing |